Question to the Department for Environment, Food and Rural Affairs:

To ask the Secretary of State for Environment, Food and Rural Affairs, pursuant to the Answer of 4 November 2025 to Question 80333, if she will make an assessment of the potential merits of funding public awareness campaigns, including advertisements at airports and ports, on (a) foot and mouth disease and (b) African swine fever.

Answered by Angela Eagle - Minister of State (Department for Environment, Food and Rural Affairs)

Biosecurity is a priority for this Government. To protect UK farmers and animals from serious diseases like Foot and Mouth Disease and African Swine Fever, we are using the Christmas period as an opportunity to remind the public about the personal imports ban on travellers from the EU and EEA countries bringing dairy and meat products to GB, that came into force earlier this year. This includes promoting awareness of the rules to the travelling public and extending our reach through partnership channels across government and with industry. Our insights survey results indicate that over 90% of respondents are aware that they should not bring back meat and dairy products from these countries.

Any decisions on funding paid campaigns will be made based on the current threat level, evidence of effectiveness and available resources, ensuring maximum impact in protecting UK biosecurity.

Question to the Department for Environment, Food and Rural Affairs:

To ask the Secretary of State for Environment, Food and Rural Affairs, pursuant to the Answer of 4 November 2025 to Question 80333 if she will take steps to help increase the audience reach of her Department's digital communications on risks of personal imports, including the risks of (a) foot and mouth disease and (b) African swine fever.

Answered by Angela Eagle - Minister of State (Department for Environment, Food and Rural Affairs)

Biosecurity is a priority for this Government. To protect UK farmers and animals from serious diseases like Foot and Mouth Disease and African Swine Fever, we are using the Christmas period as an opportunity to remind the public about the personal imports ban on travellers from the EU and EEA countries bringing dairy and meat products to GB, that came into force earlier this year. This includes promoting awareness of the rules to the travelling public and extending our reach through partnership channels across government and with industry. Our insights survey results indicate that over 90% of respondents are aware that they should not bring back meat and dairy products from these countries.

Any decisions on funding paid campaigns will be made based on the current threat level, evidence of effectiveness and available resources, ensuring maximum impact in protecting UK biosecurity.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department plans to take steps to ensure Enhertu remains available on the NHS.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Decisions on whether new medicines should be routinely funded by the National Health Service in England are made on the basis of recommendations from the National Institute for Health and Care Excellence (NICE) following an evaluation of a treatment’s costs and benefits. These are very difficult decisions to make, and it is important that they are made independently and on the basis of the available evidence.

NICE has recommended Enhertu (trastuzumab deruxtecan) for use through the Cancer Drugs Fund for the treatment of HER2-positive unresectable or metastatic breast cancer after one or more anti-HER 2 treatments and for treating HER2-positive unresectable or metastatic breast cancer after two or more anti-HER2 therapies. Enhertu is now funded for eligible patients in England through the Cancer Drugs Fund in line with NICE’s recommendations. NICE will consider the evidence collected on the use of Enhertu through the Cancer Drugs Fund into account in making recommendations for the NHS on whether it should be routinely funded by the NHS.

NICE published guidance in July 2024 on the use of Enhertu for the treatment of HER-2 low metastatic and unresectable breast cancer and was unfortunately unable to recommend it for routine NHS funding.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to improve community healthcare in rural areas.

Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)